Hematological Disorders

Treating Endothelial Function May Target Root Disease in Marfan Syndrome

February 13, 2018

The researchers found that the MFS/ATR1a-null mice showed unabated aortic root enlargement and remained responsive to losartan, despite being hypotensive and resistant to AngII vasopressor effects.

Rebinyn Now Available for the Treatment of Hemophilia B

By February 08, 2018

Rebinyn, a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life, was approved by the Food and Drug Administration (FDA) in May 2017.

Antibiotic Prophylaxis Rates Low for Pediatric Sickle Cell Patients

February 06, 2018

Data were included for 2,821 children with 5,014 person-years. The researchers found that 18 percent of children received ≥300 days of antibiotics.

FDA Approves Expanded Use for Feraheme in Iron Deficiency Anemia

By February 05, 2018

The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.

Results Released in Multi-Year IV Bevacizumab Study for HHT-Related Bleeding

February 05, 2018

After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.

Should all Syncope Patients Undergo Evaluation for Pulmonary Embolism?

January 30, 2018

At 90 days, the prevalence of venous thromboembolism varied from 0.3 to 1.37% for all patients and from 0.75 to 3.86% for hospitalized patients.

Iron Dextran Injection Recall Expanded

By January 25, 2018

The recall was initiated due to product stability testing results that did not meet specifications for iron content.

New Guidelines Available on Anticoagulation Tx for Cardiopulmonary Bypass

January 22, 2018

Recommendations for heparin dosing and monitoring, contraindications and alternatives, reversal

Surgicel Powder Absorbable Hemostat Available for Bleeding Management

By January 09, 2018

Surgicel Powder Absorbable Hemostat is a powdered adjunctive hemostat used to control disruptive bleeding.

Treating a Common Extraintestinal Manifestation of Inflammatory Bowel Disease

January 05, 2018

Mr. C, a 30-year-old male with Crohn's disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.

Siklos Approved for Pediatric Patients With Sickle Cell Anemia

By December 21, 2017

This is the first FDA approval of hydroxyurea for use in pediatric patients with sickle cell disease.

FDA Lifts Hold on Potential Hemophilia Treatment

By December 15, 2017

Fitusiran, an RNAi therapeutic targeting antithrombin (AT), is designed to lower levels of AT in order to further sufficient thrombin generation to restore hemostasis and prevent bleeding.

Case Study IDs Calciphylaxis Risk Factors, May Aid in Future Prevention

December 14, 2017

The researchers observed significant associations for lupus anticoagulant (48% positive in cases versus 5% in controls), protein C deficiency (50 versus 8%), and combined thrombophilias (62 versus 31%) with calciphylaxis among all patients.

Sickle Cell Disease Treatment Endari Soon to Be Available

By December 11, 2017

Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

Iron Deficiency Treatment in a Heart Failure Patient

December 11, 2017

A women with a 30-year history of hypertension, hyperlipidemia and an 8-year history of systolic dysfunction is hospitalized for congestion following a 5-day river cruise.

Gene Therapy Shows Promise in Factor IX Coagulant Activity for Hemophilia B

December 07, 2017

In all participants, vector-derived factor IX coagulant activity was sustained, with a mean steady-state factor IX coagulant activity of 33.7 ± 18.5%.

Possible New Marker of Kidney Disease Identified in Sickle Cell

December 05, 2017

Subsequently, 18 extracellular proteins were focused on, including CP, a protein involved in iron metabolism.

Incidence of Adverse Events Compared Among IV Iron Compounds

By December 04, 2017

It was also found that fewer all-cause ED visits or hospitalizations occurred in non-CKD patients (HR: 0.56; 95% CI: 0.45, 0.70) as well as in NDD-CKD patients (HR: 0.83; 95% CI: 0.71, 0.95) treated with ferumoxytol.

ACC: New Guidance on Managing Bleeding in Patients on Oral Anticoagulants

December 04, 2017

At each step, patient specific factors should be considered.

IV Iron Sucrose Evaluated for Iron Deficiency Anemia in Pediatric IBD

By December 01, 2017

Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions).

Ferric Carboxymaltose Tx Examined in Chronic HF Patients With Iron Deficiency

By December 01, 2017

Results demonstrated that both serum ferritin as well as transferrin saturation were significantly increased after FCM administration.

Frequency of Celiac Disease Testing Examined in Patients with IDA

By November 30, 2017

The subgroup that was most frequently tested was young Caucasian men, with 61% of respondents stating that they would implement serologic testing in this group.

NDA Under Priority Review for Thrombocytopenia in Chronic Liver Disease

By November 28, 2017

A Prescription Drug User Free Act (PDUFA) date has been set for May 21, 2018.

Hemophilic Arthropathy Treatment Gets Orphan Drug Designation

By November 27, 2017

TRM-201 (rofecoxib) is a highly potent COX-2 selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile.

Alprolix Labeling Updated With Long-Term Data, Additional Adverse Reaction

By November 27, 2017

Alprolix is a recombinant clotting factor therapy developed using Fc fusion technology to prolong circulation in the body.

Hemlibra Approved to Treat Hemophilia A With Inhibitors

By November 16, 2017

Hemlibra is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

Treating Iron Deficiency Anemia in Patients With Heart Failure

By November 16, 2017

To shed light on the often-challenging management of this common condition, MPR presented the case of a hypothetical patient to a doctor who specializes in advanced heart failure and transplant cardiology.

Effect of Treatment Delay With Tranexamic Acid Examined

November 08, 2017

Overall, 63% of bleeding deaths occurred within 12 hours of onset. There was a peak in deaths from postpartum hemorrhage at 2 to 3 hours after childbirth.

Anticoagulant Linked to Reduced Cancer Incidence

November 08, 2017

"Warfarin use may have broad anticancer potential in a large, population-based cohort of persons older than 50 years," the authors write.

Auryxia Approved for Iron Deficiency Anemia in Patients With CKD

By November 07, 2017

At any point during the 16-week efficacy period, 52.1% (n=61/117) of the Auryxia treated group demonstrated hemoglobin levels of ≥1g/dL compared to 19.1% (n=22/115) of the placebo group.